April 8, 2008

News Release

For Immediate Release

THE JENEX CORPORATION ISSUES STATUS REPORT ON FINANCING

Burlington, Ontario – The Jenex Corporation (“Jenex” or the “Corporation”) TSX Venture Exchange: JEN) reports that the previously announced “best efforts” private placement has expired and will not proceed. Management continues to search for new opportunities to fund the world-wide commercialization of their products.

About The Jenex Corporation

Jenex has a non-invasive Medical Device that prevents cold sore outbreaks. The interceptCS(TM) Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.

In addition to interceptCS, Jenex markets Therapik(R) for insect stings & different insects. Therapik is approved in Canada and the United States and Australia, as well as having CE Mark approval in the European Union countries.  Jenex's Thermal Therapy technology is patented in the U.S, Canada, Australia, & Europe.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

Cautionary Statements

This news release report contains “forward-looking statements”, within the meaning of the United States Private Securities Litigation Reform Act of 1995 and similar Canadian legislation, concerning the business, operations and financial performance and condition of Jenex. Forward-looking statements include, but are not limited to, statements with respect to the benefits of the offering and option transaction.  Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Jenex to be materially different from those expressed or implied by such forward-looking statements, including but not limited to risks related to: not realizing on the anticipated benefits from the transaction or not realizing on such anticipated benefits within the expected time frame; risks related to patents and technology; and other risks of the pharamaceutical industry.  Although management of Jenex has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.  Accordingly, readers should not place undue reliance on forward-looking statements.  Jenex does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws.

More information about the Corporation can be found at:

The Jenex Corporation

207 – 940 Sheldon Court

Burlington, Ontario

L7L 5K6

Michael A. Jenkins, President

Telephone: (905) 632-3830

Facsimile: (905) 632-3774

Email: jenex@jenexcorp.com

            www.jenexcorp.com